Several proteasome inhibitors are currently in clinical use or under investigation. Some of the most well-known include:
Bortezomib (Velcade): The first proteasome inhibitor approved for clinical use, primarily used in multiple myeloma and mantle cell lymphoma. Carfilzomib (Kyprolis): A second-generation proteasome inhibitor, also used in multiple myeloma. Ixazomib (Ninlaro): An orally bioavailable proteasome inhibitor, used in combination with other agents for multiple myeloma.
